Handled the intellectual property aspects of a $46 million deal between our client, Nabi Biopharmaceuticals, and GlaxoSmithKline, relating to the sale of a vaccine against S. aureus, which will be critical in the fight against the multidrug-resistant bacterium known as MRSA.
Developed a patent portfolio for international biotechnology company that contained over 75 patent families, including applications and patents to protect tools for target identification and validation, novel therapeutic targets, as well as vaccine-based and antibody-based therapeutics directed to those targets. Technology was one of the first applications of bioinformatics for target identification. It was the key intellectual property for this division of the company.
Licensing of biotechnology drug with up-front payment of $100 million. Represented acquiring company, a global pharmaceutical company, in IP diligence and drafting transaction agreements.